NorthWest Biotherapeutics Inc (NWBO)

[dmb2]

I wonder what data would have averted this negative response, there is much positive in these results, just not as positive as had been expected given the interim data. So expectations were set higher, they now have to be re-grounded and these results are good.

DCVax-L has a positive impact on GBM patients with no safety constraints. It is up to NWBO to determine next steps to get the approval process jumpstarted and next platform development steps defined. I believe they are ahead of this and we will find out how far ahead shortly.